Methods for topical delivery of prostaglandins to subcutaneous fat

• US 9,849,179 B2
• Filed: 05/01/2015
• Issued: 12/26/2017
• Est. Priority Date: 05/10/2013
• Status: Active Grant

• Current Assignee: Topokine Therapeutics, Inc. (Abbvie Incorporated)
• Original Assignee: Topokine Therapeutics, Inc. (Abbvie Incorporated)
• Inventors: Singer, Michael S., Kalayoglu, Murat V.
• Primary Examiner(s): Weddington, Kevin E
• Application Number:
  US14/702,365
• Publication Number:
  US 20150231251A1
• Time in Patent Office: 970 Days
• Field of Search: 514573
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/23 of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61K 47/06 Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject.

Claims

1. A method for reducing body fat in a subject, the method comprising administering to the subject a composition comprising latanoprost, isopropyl myristate, and petroleum jelly.

2. The method of claim 1, wherein the method locally reduces body fat in the subject.

3. The method of claim 1, wherein the method reduces subcutaneous fat in the subject.

4. The method of claim 1, wherein the composition consists essentially of latanoprost, isopropyl myristate, and petroleum jelly.

5. The method of claim 1, wherein the latanoprost concentration is between about 0.001% and about 1% w/w, inclusive.

6. The method of claim 5, wherein the latanoprost concentration is between about 0.01% and about 0.5% w/w, inclusive.

7. The method of claim 1, wherein the isopropyl myristate concentration is between about 1% and about 20% w/w, inclusive.

8. The method of claim 7, wherein the isopropyl myristate concentration is between about 1% and about 10% w/w, inclusive.

9. The method of claim 5, wherein the isopropyl myristate concentration is between about 1% and about 20% w/w, inclusive.

10. The method of claim 9, wherein the isopropyl myristate concentration is between about 1% and about 10% w/w, inclusive.

11. The method of claim 1, wherein the petroleum jelly concentration is between about 70% and about 99% w/w, inclusive.

12. The method of claim 5, wherein the petroleum jelly concentration is between about 70% and about 99% w/w, inclusive.

13. The method of claim 1, wherein the composition further comprises a preservative.

14. The method of claim 13, wherein the preservative is chlorobutanol.

15. The method of claim 1, wherein the composition is sterile.

16. The method of claim 1, wherein the latanoprost concentration is between about 0.001% and 1% w/w, inclusive;

the isopropyl myristate concentration is between about 1% and about 10% w/w, inclusive; and

the petroleum jelly concentration is between about 70% and about 99% w/w, inclusive.

17. The method of claim 1, wherein the step of administering is performed about once a day.

18. The method of claim 1, wherein the step of administering comprises administering the composition to the face, chin, neck, arms, abdomen, chest, breast, buttocks, hips, thighs, legs, and/or knees.

19. The method of claim 1, wherein the step of administering comprises administering the composition to the eyelids.

20. The method of claim 1, wherein the step of administering comprises administering the composition to the submental region.

21. The method of claim 1, wherein the latanoprost concentration is between about 0.03% and about 0.1% w/w, inclusive.

22. The method of claim 21, wherein the composition consists essentially of latanoprost, isopropyl myristate, and petroleum jelly.

23. The method of claim 16, wherein the latanoprost concentration is between about 0.03% and about 0.1% w/w, inclusive.

24. The method of claim 23, wherein the composition consists essentially of latanoprost, isopropyl myristate, and petroleum jelly.

25. The method of claim 1, wherein the latanoprost concentration is about 0.1% w/w.

26. The method of claim 25, wherein the composition consists essentially of latanoprost, isopropyl myristate, and petroleum jelly.

27. The method of claim 16, wherein the latanoprost concentration is about 0.1% w/w.

28. The method of claim 27, wherein the composition consists essentially of latanoprost, isopropyl myristate, and petroleum jelly.